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Is it the agent or the blood pressure level that matters for re-
nal and vascular protection in chronic nephropathies? Over the
recent years, it has been clearly documented that hypertension
and proteinuria are the major factors responsible for progres-
sion of chronic kidney disease (CKD). Therefore, a target BP
of at least 130/80 mm Hg has been suggested in order to re-
duce the rate of progression and cardiovascular mortality. Some
antihypertensive agents, such as ACE inhibitors (ACEIs), an-
giotensin II receptor blockers (ARBs), and perhaps calcium
channel blockers (CCBs), may also be capable of reducing CKD
progression because they halt some of the pathogenetic mech-
anisms involved in renal damage, some of which is unrelated
to reduction of proteinuria, per se. Although this specific effect
seemed to be partially independent of blood pressure reduction,
it remains controversial whether these drugs are really superior
to other antihypertensive agents when blood pressure values
recommended by guidelines are achieved. This issue is still a
matter of debate because in published trials, target and achieved
blood pressure values were constantly higher than those recom-
mended today. Nevertheless, available findings seem to indicate
that the renoprotective effect of these agents is at least partially
independent of a better BP control. The only way to definitely
solve this issue would be a new randomized trial. However, the
clinical relevance of this trial is debatable, considering that we
need all the drugs available to reach these recommended BP
values.
Hypertension is not only an important presenting fea-
ture of chronic kidney disease (CKD), but together with
proteinuria, it is also a major factor contributing to its
progression. As a consequence, effective antihyperten-
sive therapy is the cornerstone of treatment in CKD pa-
tients, apart from treatment, if possible, of the primary
disease. Besides this, it is now well established that some
antihypertensive drugs have additional renoprotective
effects that seem to be at least partially independent of
blood pressure (BP) reduction. However, in the major-
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ity of large trials, target and achieved BP values were
constantly higher than those recommended today. More-
over, the BP values were often lower in the experimen-
tal groups [ACE inhibitors (ACEIs) or angiotensin II
receptor blockers (ARBs)] compared with the control
groups. Given these considerations, it is a matter of de-
bate whether these agents would still be superior to other
antihypertensive agents when recommended BP values
were really achieved.
Hypertension and chronic kidney disease progression
A number of retrospective longitudinal [1, 2, 3] and
cross-sectional [4] studies have provided data showing
that the higher the BP, the faster the progression of renal
disease. The results of the largest study, which included al-
most 7000 patients, indicated that the worsening in renal
function correlated with BP values even within the nor-
motensive range [4]; another study found that this ob-
servation was more evident for systolic (SBP) than for
diastolic blood pressure (DBP) [5].
It seems that the rate of progression is a continuous
function of mean arterial pressure (MAP), which implies
that renal protection is a continuous function of BP down
to the low end of the normal range. Locatelli et al [6, 7]
found that the patients with rapid progression, or those
who reached an end point (doubling of baseline serum
creatinine or need for dialysis), had significantly higher
baseline BP values than patients with slow progression.
However, this relationship was not confirmed by a mul-
tivariate regression analysis [6]. Other studies failed to
show a significant relationship between the progression
of CKD and BP values during the course of the disease
[8, 9].
In recent years, particular attention has been paid to
the deleterious effects of SBP on kidney function. Jafar
et al reported a meta-analysis [10] assessing the effect of
ACEIs on the progression of nondiabetic renal disease
on 1860 patients. In a secondary analysis [11] of this data
they found that both baseline and follow-up values of SBP
and DBP, together with proteinuria, were significantly
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related to CKD progression. In the multivariable analy-
sis, however, DBP was not confirmed as an independent
risk factor. Interestingly enough, the graphic plot of the
relative risks of progression according to SBP values had
a U shape, with the lowest risk for kidney disease pro-
gression at SBP levels of between 110 and 129 mm Hg.
The relationship between BP and risk for CKD progres-
sion differed according to proteinuria: in patients with
higher levels of proteinuria during follow-up, the optimal
current SBP seemed to be 110 to 119 mm Hg, whereas
in patients with lower levels of proteinuria, the risk for
kidney disease progression remained relatively constant
over a wide range of SBP (110-160 mm Hg), increasing
only for lower or higher values.
Similar findings were obtained in a post-hoc analysis of
the RENAAL study [12]: the risk of having a renal out-
come was significantly increased at all SBP levels >140
mm Hg at baseline. It was nearly doubled at SBP levels
≥160 mm Hg compared to the reference values of <130
mm Hg. The values of DBP at baseline were not signif-
icantly related to the risk of having a renal end point.
Interestingly enough, baseline pulse pressure (PP) seems
of greater importance (a PP of ≥70 mm Hg increased the
risk of all renal end points, including ESRD or death).
As underlined by the authors [12], this suggests that in-
creased PP values are associated with reduced intrarenal
autoregulation, and possibly to a loss of the kidney’s abil-
ity to adjust to changes in systemic blood pressure.
Blood pressure reduction and progression of CKD
Over the last decade, a number of trials have been per-
formed to assess the degree of BP reduction needed to
achieve renoprotection. The Modification of Diet in Re-
nal Disease (MDRD) study [13] was the first large, ran-
domized trial performed on this topic. The 840 patients
with CKD were stratified into 2 groups according to base-
line renal function, and were randomized to 2 different
levels of dietary protein intake. In addition, the patients
were also randomized to usual BP control (MAP ≤107
mm Hg in subjects aged ≤60 years, or ≤113 mm Hg in
subjects older than 60 years) or stricter BP control (MAP
≤92 mm Hg in subjects aged ≤60 years, or ≤98 mm Hg
in subjects older than 60 years) [13]. In study A (baseline
GFR 25-55 mL/min), the mean decline in GFR was faster
in the first 4 months of follow-up, and slower thereafter
in the strict group than in the group with usual BP con-
trol, while in patients with more advanced CKD (study
B: baseline GFR 13-24 mL/min), the decline of GFR was
linear, and did not differ significantly between the 2 BP
groups. The patients with higher levels of baseline pro-
teinuria received greater benefits from being assigned to
a low BP target. According to an estimate [14], a stricter
BP control could delay the time to ESRD by 1.24 years
over a period of 9.4 years. In study B, only 0.43 years
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Fig. 1. MAP distribution during follow-up in the low and usual blood
pressure groups of the MDRD study [18]. This estimate has been ob-
tained assuming a Gaussian distribution of BP values during follow-up
(considering the high number of patients). We then calculated from
the characteristics of normal distributions the percentage of patients
with MAP values higher than the threshold of 97 mm Hg (equivalent
to 130/80 mm Hg), 101 mm Hg (equivalent to 135/85 mm Hg), and 107
mm Hg (equivalent to 140/90 mm Hg), respectively.
could be gained with a strict BP control, for a mean pro-
jected period of 3.6 years. It is worth noting that the ef-
fects of BP control in the MDRD study [13] may have
been partly confounded by an imbalance in the propor-
tion of patients receiving ACEIs in the 2 groups (54%
of the patients in the low BP group, but only by 34% in
the usual BP group). In addition, a large percentage of
patients did not reach the recommended BP target. We
have estimated that more than half of the patients in the
usual BP group had DBP >95 mm Hg; this percentage
was reduced to only 30% in the group randomized to the
strict BP control (Fig. 1).
The role of BP control in CKD progression has also
been studied in diabetic patients. The UK Prospec-
tive Diabetes Study (UKPDS) was a randomized
controlled trial aimed at evaluating whether “tight BP
control” (SBP/DBP <150/85 mm Hg) was able to pre-
vent macrovascular and microvascular complications in
patients with type 2 diabetes compared with “less tight
control” (SBP/DBP <180/105 mm Hg) [15]. After 9 years
of follow-up, the patients assigned to “tight BP control”
had a 37% reduction in their relative risk of develop-
ing microvascular end points compared with those as-
signed to “less tight BP control.” However, these BP
values are much higher than those recommended to-
day. The effect on renal disease–related end points was
less convincing than that on the combined microvascular
end points, probably because the former were only in-
frequent, since patients were included in the study very
early in the course of diabetes. More recently, the results
of the African American Study of Kidney Disease and
Hypertension (AASK) study have been published [16].
This study was designed to assess the impact of 2 BP goals
(102 to 107 mm Hg and ≤92 mm Hg, respectively) and 3
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different drug regimens (ramipril, amlodpine, and meto-
prolol) on the progression of hypertensive nephrosclero-
sis in 1094 African Americans. However, in this specific
population, intervention aimed at a lower BP goal did
not result in a better outcome compared to the usual con-
trol. In particular, no difference was found between the
mean GFR slope and the percentage of patients reach-
ing the clinical composite end point (reduction in GFR
of 50% from baseline, ESRD, or death) in the 2 groups.
For each outcome, only slight trends favoring the lower
BP goal were observed in proteinuric patients (base-
line urinary protein to creatinine ratio >0.22). These
negative findings could be partially explained by the
fact that the selected patients had only mild proteinuria
(mean value at baseline of 0.61 g/24h in males, and 0.36-
0.46 g/24h in females). As already pointed out by a sec-
ondary analysis of the MDRD study published some
years ago, the rate of decline in GFR was unrelated to
follow-up BP in patients with baseline proteinuria of less
than 1.0 g/day [17]. In any case, in the AASK trial, a
lower BP target had a beneficial effect on proteinuria
levels, which decreased by 17% in the first 6 months of
the study. In contrast, in the group assigned to usual blood
pressure control, proteinuria increased by 7% [16].
Does the blockade of the renin-angiotensin system
have additional effects unrelated to lowering
of blood pressure?
The clear relationship between urinary protein excre-
tion and blood pressure levels is presumably explained
by the transmission of high systemic BP to the dis-
eased glomeruli. Therefore, any type of antihypertensive
therapy will potentially decrease proteinuria. However,
some agents may be capable of reducing CKD pro-
gression because they halt other pathogenetic mecha-
nisms involved in glomerular and tubulointerstitial renal
damage; this is particularly true for drugs blocking the
renin-angiotensin system, as demonstrated by a num-
ber of clinical trials [18–22]. However, the majority of
the studies have been criticized because SBP and DBP
values achieved with the experimental treatment were
lower than those obtained during standard antihyperten-
sive therapy. Presently recommended blood pressure val-
ues were very seldom achieved.
In the Angiotensin-Converting-Enzyme Inhibition in
Progressive Renal Insufficiency (AIPRI) study [19], the
effect of benazepril in reducing CKD progression was
striking, according to the previously mentioned estimate
[14]. Administering this drug over a period of nearly
11 years would lead to a delay in the need of renal re-
placement therapy by nearly 4 years. Even if benazepril
treatment led to lower BP values than control treatment
despite adjustment for changes in DBP, the overall risk re-
duction for progression of renal disease in the benazepril
group was still significant. When SBP at baseline and dur-
ing follow-up was included together with DBP in a sec-
ondary analysis of the AIPRI data [23], it was found that
DBP at baseline (relative risk increase of 6% for each mm
Hg increase) and SBP changes from baseline throughout
follow-up (relative risk increase of 3% for each mm Hg
increase) were independently associated with the primary
end points (the doubling of serum creatinine from base-
line or the need of renal replacement therapy); when all of
the covariates were considered, a trend toward indepen-
dent renoprotection by ACEIs was still present (relative
risk reduction of 20%, P = 0.39). Interestingly enough,
the reduction in SBP from baseline during follow-up was
significantly associated with the reduction in proteinuria
levels (P = 0.013). In turn, these were strongly correlated
with renal outcome. The reduction in proteinuria was sig-
nificantly greater in the benazepril than in the control
group throughout the entire blood pressure range.
The effect of ACEIs on progression of nondiabetic
renal disease has recently been re-evaluated in the
meta-analysis of patient-level data by Jafar et al [11],
including 11 randomized trials and a total of 1860 pa-
tients. Throughout the entire follow-up, mean SBP was
significantly lower in the ACEI than in the control group
(139 ± 16 mm Hg vs. 144 ± 16 mm Hg); the difference in
mean DBP between the 2 groups was lower (85 ± 7 mm
Hg vs. 87 ± 8 mm Hg), but still statistically significant (P <
0.01). In addition, as already pointed out for the MDRD
study [13], nearly 50% of the patients in the ACEI group,
and 60% in the control group, did not achieve the target
SBP of <140 mm Hg. After adjustment for changes in BP
during follow-up, the treatment effect remained signifi-
cant in multivariate models, suggesting that the renopro-
tective effect is at least partially independent of better BP
control.
The RENAAL [21] and IDNT [22] studies have
demonstrated that blocking the effects of angiotensin II
through ARBs is renoprotective in patients with type 2
diabetes. Since these trials were designed more recently
than those on the effect of ACEIs on CKD progression,
BP targets were slightly lower (<140/90 and <135/85 mm
Hg, respectively). In addition, even if time averaged dif-
ferences in BP between the losartan and placebo group
were observed in the RENAAL study during the first 2
years of follow-up, later on they were not present any-
more [21]. In the IDNT study, similar BP control was re-
ported in the 2 groups throughout follow-up [22]. In both
studies, the reduction in the risk of reaching the primary
composite end points remained unchanged after adjust-
ment for BP [21, 22], possibly indicating that the effect of
ARBs, per se, largely exceeds that of BP difference. How-
ever, even in these 2 trials, a high percentage of patients
did not reach the recommended BP targets, in particular
for SBP, despite multidrug treatment in the majority of
them. Even if in these trials a significant reduction in the
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Table 1. Number of patients to be treated in the RENAAL [21] and
IDNT [22] trials in order to avoid one end point
Study End point Drug Patients Events RR NNT
IDNT Primary Irbesartan 579 189 0.84 16
compositea Placebo 569 222
IDNT Primary Irbesartan 579 189 0.79 12
compositea Amlodipine 567 233
IDNT Doubling of Irbesartan 579 98 0.71 15
SCrb Placebo 569 135
IDNT Doubling of Irbesartan 579 98 0.67 12
SCrb Amlodipine 567 144
RENAAL Composite Losartan 748 327 0.93 29
outcomec Placebo 762 359
aThe doubling of the baseline serum creatinine concentration, the develop-
ment of end-stage renal disease, or death from any cause.
bThe doubling of the baseline serum creatinine concentration.
cThe doubling of the baseline serum creatinine concentration, end-stage renal
disease, or death.
relative risk of reaching renal end points was achieved,
it is sobering that the number of patients needed to be
treated in order to prevent an end point is quite high,
indicating that these agents cannot be considered to pro-
vide a definite cure for CKD (Table 1).
Combination therapy
In recent years it has been hypothesized that com-
plete inhibition of the renin-angiotensin system by dual
blockage with ACEIs and ARBs would be more benefi-
cial in the management of progressive CKD than either
agent alone. The COOPERATE study [24], which has
recently been published, seems to confirm that combina-
tion treatment safely retards progression compared with
monotherapy. This was a randomized, controlled trial,
enrolling 263 Japanese patients with nondiabetic renal
disease, who were assigned to losartan (100 mg daily),
trandolapril (3 mg daily), or a combination of both drugs
at equivalent doses. After 3 years of follow-up, 11% of
the patients on combination treatment reached the com-
bined primary end point of the doubling of serum cre-
atinine from baseline or ESRD compared with 23% of
those treated with trandolapril alone (hazard ratio 0.38,
P = 0.018), and 23% of those treated with losartan alone
(hazard ratio 0.40, P = 0.016). It is worth noting that
the authors of this trial succeeded in obtaining adequate
BP control in the majority of the patients (mean BP of
128 ± 9/80 ± 4 mm Hg). Even more interestingly, BP
values were similar in the 3 groups [25]. This is the first
clear evidence that the renoprotective effect of the renin-
angiotensin system blockade is independent of BP reduc-
tion, and persists even in the presence of adequate BP
control. However, to fully solve the controversy whether
the effect of ACEIs or ARBs on renal protection is me-
diated or not by blood pressure reduction, and whether
this effect persists at the recommended BP target, fur-
ther studies would be needed to test ACEIs or ARBs
compared to placebo associated with conventional anti-
hypertensive therapy under this experimental condition.
Unfortunately, today this kind of study is not longer fea-
sible from the ethical point of view, at least in proteinuric
patients with CKD.
CONCLUSION
ACEIs and ARBs are effective in reducing proteinuria,
and preventing the progression of renal damage in CKD
patients. This effect seems at least partially independent
of blood pressure reduction. However, it is still unclear
whether this also applies at the currently recommended
target blood pressure values, as a large percentage of pa-
tients did not achieve an optimal BP control. In addition,
in the majority of the trials performed with these agents,
no data were available on 24-hour BP control, which re-
flects the actual BP control much better than casual BP
measurements, considering that BP values were usually
measured 24 hours after drug administration, when the
treatment effect was nearly exhausted. As a result, quite
large differences in BP values between treatment groups
in the hours following drug administration might not have
been detected, which might possibly have explained a
treatment benefit.
The combination of ACEIs and ARBs agents seems to
be an interesting therapeutic option.
Finally, it is debatable whether it is clinically relevant
to investigate whether BP reduction, per se, is equally
or more effective than ACEIs or ARBs in slowing down
CKD progression in patients who reach recommended
blood pressure targets, considering that we need all the
drugs available to reach these recommended BP values.
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